JP2013522239A - 注射用薬物送達システム - Google Patents

注射用薬物送達システム Download PDF

Info

Publication number
JP2013522239A
JP2013522239A JP2012557295A JP2012557295A JP2013522239A JP 2013522239 A JP2013522239 A JP 2013522239A JP 2012557295 A JP2012557295 A JP 2012557295A JP 2012557295 A JP2012557295 A JP 2012557295A JP 2013522239 A JP2013522239 A JP 2013522239A
Authority
JP
Japan
Prior art keywords
polysaccharide
formulation
group
api
glucopyranose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012557295A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522239A5 (https=
Inventor
ティモシー エム． クロケ，
ジョラン スレイガー，
ラクシュマ ガンドラパリー レディー，
デイビッド イー． バブコック，
Original Assignee
サーモディクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by サーモディクス，インコーポレイテッド filed Critical サーモディクス，インコーポレイテッド
Publication of JP2013522239A publication Critical patent/JP2013522239A/ja
Publication of JP2013522239A5 publication Critical patent/JP2013522239A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
JP2012557295A 2010-03-12 2011-03-11 注射用薬物送達システム Pending JP2013522239A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31366610P 2010-03-12 2010-03-12
US61/313,666 2010-03-12
PCT/US2011/028195 WO2011112996A2 (en) 2010-03-12 2011-03-11 Injectable drug delivery system

Publications (2)

Publication Number Publication Date
JP2013522239A true JP2013522239A (ja) 2013-06-13
JP2013522239A5 JP2013522239A5 (https=) 2014-04-24

Family

ID=44148866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012557295A Pending JP2013522239A (ja) 2010-03-12 2011-03-11 注射用薬物送達システム

Country Status (5)

Country Link
US (1) US20110229457A1 (https=)
EP (1) EP2544658A2 (https=)
JP (1) JP2013522239A (https=)
CA (1) CA2792771A1 (https=)
WO (1) WO2011112996A2 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026018920A1 (ja) * 2024-07-18 2026-01-22 国立大学法人九州大学 凍結乾燥装置、および、凍結乾燥試料とその製造方法

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012347926B2 (en) * 2011-12-05 2018-03-15 Incept, Llc Medical organogel processes and compositions
US20140309287A1 (en) * 2012-12-06 2014-10-16 Regado Biosciences, Inc. Oligonucleotide formulation
CN106573133B (zh) 2014-08-19 2020-03-03 加利福尼亚大学董事会 用于局部药物递送的植入物及其使用方法
US20180371158A1 (en) * 2015-12-18 2018-12-27 Abraham Joy Peptidomimetic polymers as controlled release matrices for small molecules, biologicals, synthetic or semi-synthetic macromolecules
WO2019008991A1 (ja) * 2017-07-07 2019-01-10 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
JP6952279B2 (ja) * 2017-07-07 2021-10-20 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
KR20200024758A (ko) * 2017-07-07 2020-03-09 파나소닉 아이피 매니지먼트 가부시키가이샤 정보 제공 방법, 정보 처리 시스템, 정보 단말, 및 정보 처리 방법
CN110537097B (zh) * 2017-07-07 2022-03-08 松下知识产权经营株式会社 信息提供方法、信息处理系统、信息终端及信息处理方法
WO2019008970A1 (ja) * 2017-07-07 2019-01-10 パナソニックＩｐマネジメント株式会社 情報提供方法、情報処理システム、情報端末、及び情報処理方法
WO2020180555A1 (en) * 2019-03-05 2020-09-10 Dow Global Technologies Llc Polyethyleneglycol derivatives for inducing caspase activity
US11173291B2 (en) 2020-03-20 2021-11-16 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
JP7665645B2 (ja) 2020-03-20 2025-04-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 局所的な薬物送達のための移植可能な薬物送達デバイス
US11344526B2 (en) 2020-03-20 2022-05-31 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
US11338119B2 (en) 2020-03-20 2022-05-24 The Regents Of The University Of California Implantable drug delivery devices for localized drug delivery
CN111956638B (zh) * 2020-08-06 2023-01-24 上海宛文创业孵化器管理合伙企业(有限合伙) 蓓萨罗丁或/和其药学上可接受的盐在制备抗肺动脉高压药物中的应用
US11912696B2 (en) 2021-10-01 2024-02-27 Promega Corporation Compounds and methods for detection of nitric oxide
CN116870238B (zh) * 2023-08-25 2025-12-26 中国海洋大学 一种抑菌介孔淀粉止血粉及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509146A (ja) * 1996-12-20 2001-07-10 アルザ コーポレイション ゲル組成物および方法
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
JP2008501757A (ja) * 2004-06-09 2008-01-24 ノバルティス アクチエンゲゼルシャフト ６００ダルトン未満の分子量を有するポリエチレングリコールを含む医薬組成物
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
JP2009529967A (ja) * 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4433101A1 (de) * 1994-09-16 1996-03-21 Bauer Kurt Heinz Prof Dr Wasserlösliche Dextranfettsäureester und ihre Verwendung als Solubilisatoren
US6224893B1 (en) * 1997-04-11 2001-05-01 Massachusetts Institute Of Technology Semi-interpenetrating or interpenetrating polymer networks for drug delivery and tissue engineering
US6472512B1 (en) * 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
EP1481695A1 (en) * 1999-10-15 2004-12-01 Genetics Institute, LLC Formulations of hyaluronic acid for delivery of osteogenic proteins
US6703040B2 (en) 2000-01-11 2004-03-09 Intralytix, Inc. Polymer blends as biodegradable matrices for preparing biocomposites
ATE519494T1 (de) * 2000-02-08 2011-08-15 Allergan Inc Pharmazeutische zusammensetzungen mit botulinum- toxin
JP4817088B2 (ja) * 2000-10-10 2011-11-16 株式会社林原生物化学研究所 塞栓材料
AU2002320122B2 (en) * 2001-06-21 2007-07-26 Genentech, Inc. Sustained release formulation
WO2003072157A1 (en) * 2002-02-21 2003-09-04 Encelle, Inc. Immobilized bioactive hydrogel matrices as surface coatings
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
DE102004021240B4 (de) * 2004-04-30 2008-07-31 Infineon Technologies Ag Verfahren zur Herstellung einer Halbleiter-Schaltungsanordnung in BiCMOS-Technologie
WO2009005718A1 (en) * 2007-06-28 2009-01-08 Surmodics, Inc. Polypeptide microparticles having sustained release characteristics, methods and uses
WO2010141553A1 (en) * 2009-06-02 2010-12-09 Surmodics, Inc. SILANE-FUNCTIONALIZED HYDROPHOBIC a(1→4)GLUCOPYRANOSE POLYMERS AND POLYMERIC MATRICES FOR IMPLANTATION OR INJECTION

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001509146A (ja) * 1996-12-20 2001-07-10 アルザ コーポレイション ゲル組成物および方法
JP2004511431A (ja) * 2000-06-28 2004-04-15 アトゥル・ジェイ・シュクラ 生物活性物質を含む生分解性ビヒクルおよび送達システム
JP2008501757A (ja) * 2004-06-09 2008-01-24 ノバルティス アクチエンゲゼルシャフト ６００ダルトン未満の分子量を有するポリエチレングリコールを含む医薬組成物
JP2008524235A (ja) * 2004-12-15 2008-07-10 キューエルティー ユーエスエー，インコーポレイテッド． オクトレオチド化合物の徐放性送達処方物
JP2009529967A (ja) * 2006-03-15 2009-08-27 サーモディクス，インコーポレイティド 天然生分解性ポリサッカライドの疎水性誘導体及びそれらの使用

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026018920A1 (ja) * 2024-07-18 2026-01-22 国立大学法人九州大学 凍結乾燥装置、および、凍結乾燥試料とその製造方法

Also Published As

Publication number Publication date
CA2792771A1 (en) 2011-09-15
WO2011112996A2 (en) 2011-09-15
WO2011112996A3 (en) 2011-11-10
US20110229457A1 (en) 2011-09-22
EP2544658A2 (en) 2013-01-16

Similar Documents

Publication Publication Date Title
JP2013522239A (ja) 注射用薬物送達システム
Li et al. Biodegradable and injectable hydrogels in biomedical applications
Kim et al. Natural and synthetic biomaterials for controlled drug delivery
Prabaharan et al. Chitosan-based particles as controlled drug delivery systems
Ruel-Gariepy et al. Characterization of thermosensitive chitosan gels for the sustained delivery of drugs
US9205046B2 (en) Enhanced stability of inverse thermal gelling composite hydrogels
Villanueva et al. Dendrimers as a promising tool in ocular therapeutics: Latest advances and perspectives
Bader et al. Polysialic acid-based micelles for encapsulation of hydrophobic drugs
Aminabhavi et al. Production of chitosan-based hydrogels for biomedical applications
Alhaique et al. Polysaccharide-based self-assembling nanohydrogels: An overview on 25-years research on pullulan
WO2007135164A1 (en) Nanoparticles of chitosan and hyaluronan for the administration of active molecules
WO2008136536A1 (ja) 化学架橋ヒアルロン酸誘導体を含むハイブリッドゲルおよびそれを用いた医薬組成物
CA2703807A1 (en) Enhanced stability of inverse thermal gelling composite hydrogels
US20100260846A1 (en) Particles for delivery of nucleic acids and related devices and methods
Biswas et al. Polymers and their engineered analogues for ocular drug delivery: enhancing therapeutic precision
JP2013530235A (ja) 核酸の送達を向上させるための組成物および方法
US9949928B2 (en) Biodegradable copolymers, systems including the copolymers, and methods of forming and using same
Siafaka et al. Polymer based gels: Recent and future applications in drug delivery field
EP1891941A1 (en) Aqueous gels comprising microspheres
CN101448489A (zh) 用于活性分子给药的壳聚糖和乙酰透明质酸的纳米颗粒
US8697105B2 (en) Injectable drug delivery formulation
Moscovici1 et al. Nanocellulose and nanogels as modern drug delivery systems
Vora et al. Injectable depot-forming hydrogels for long-acting drug delivery
Ottenbrite et al. Polymer systems for biomedical applications: An overview
Shojaee Gellan gumbased nanosystems for therapeutic applications

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131112

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150302

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151006